Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. RADNOR, Pa.–(BUSINESS Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinical trials examining the efficacy of cannabinoids for ASD? 17 Aug 2021. Fletcher S. See the Answer.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

Cannabis Law Report

DECEMBER 7, 2021

Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article. Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Metrics details.

Safety 52

Safety Cannabinoids Events Data 52

Canna Law Blog

NOVEMBER 15, 2021

There was a fascinating panel on the use of ketamine treatments for, among other things, depression and anxiety disorders. We continue to see an uptick in ketamine clinic transactions (the complexities of which we have written about extensively ). Pharmaceutical start-ups are betting on the treatment potential of psychedelics.

Clinical Trials 98

Clinical Trials Treatment Microdosing Pharmaceutical 98

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. RYAH Group Inc.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. Although the overarching market is still relatively new, much like the cannabis boom a few years ago the psychedelics space is growing at an unprecedented rate.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

The Cannigma

MARCH 7, 2022

A recent 2021 review of the literature found that there is simply no substantial evidence to back CBN’s claim to sedation and that more human research is needed. What can the current clinical trials tell us? Those enrolled in the study will receive 28 days of treatment and then be assessed by pain-rating scales.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Cannabis Law Report

DECEMBER 26, 2021

December 17, 2021 ·. – December 16, 2021) – Entheon Biomedical Corp. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. US Provisional Patent Filed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The primary endpoint of this Phase 1 trial was safety and tolerability. During the six months ended September 30, 2021, the Company raised approximately $4.1

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

AUGUST 3, 2021

The Shares were offered in each of the provinces of Canada, excluding Québec, pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. Vigorous scientific research and clinical trials are needed.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. NEW YORK , June 4, 2021 /PRNewswire/ — AIkido Pharma Inc. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

NOVEMBER 19, 2021

19, 2021 /CNW/ – PsyBio Therapeutics Corp. “These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

OCTOBER 13, 2021

The PCT filing also includes support for future research programs respecting various systems which seek to minimize negative side effects in psychedelic psychotherapy patients, methods that enable lower and sub-psychedelic doses without impacting treatment efficacy and increasing the long-term efficacy of psychedelic sessions. About Cybin.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

JUNE 14, 2022

Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD. There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow. Ahead of the launch, PAREA Chair Prof.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Yaden & Roland R. Mitchell et al., TIMES (Nov.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. March 8, 2021). See June 8, 2021 Order, AIMS Institute et al. Id ; 21 CFR 312.1-10;

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

OCTOBER 9, 2021

Session of 2021 – 2022 Regular Session. Posted: July 26, 2021 12:18 PM. As traditional treatment has proven inadequate at both the individual and public health level, the Commonwealth has a responsibility to research alternative options. Read more at Marijuana Moment. House of Representatives. MEMORANDUM.

Therapy 52

Therapy Clinical Trials Treatment Legislation 52

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

JUNE 25, 2021

DUBLIN–(BUSINESS WIRE)–The “Skin Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030” report has been added to ResearchAndMarkets.com’s offering. billion in 2021 at a compound annual growth rate (CAGR) of 11.8%. The global skin cancer drugs market is expected to grow from $1.44

Research and Development 84

Research and Development Therapy Pharmaceutical Clinical Trials 84

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In May 2021, a Nature Medicine study showed the benefits of MDMA in relieving post-traumatic stress disorder. [4] 5] The Journal of the American Medical Association published similar findings in May 2021. [6].

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

JULY 1, 2021

Launched in summer 2021 with a generous grant from the Saisei Foundation, the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School will advance evidence-based psychedelics law and policy. The Project. Jeannie Suk Gersen HLS.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

OCTOBER 26, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., said Dr. Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1). Nov 24 2021.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 1, 2021

Company remains on track for potential approval of Vicineum™ in the US in August 2021. Hoff and Dr. McLin and four additional new employees between June 1, 2021 and June 14, 2021 pursuant to which an aggregate of up to 1,995,000 shares of Sesen Bio common stock will be purchasable upon vesting. CAMBRIDGE, Mass.–(BUSINESS

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

JULY 14, 2021

(“ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. ImmunoFlex’s believes that the immune system changes observed in this clinical study are beneficial changes with the potential to improve immune system competence. federal law.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

The Cannigma

AUGUST 26, 2021

This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness. In addition, as of early 2021 , it is legal to purchase CBD oil over the counter in Australia. In addition, as of early 2021 , it is legal to purchase CBD oil over the counter in Australia. Costs of medical marijuana.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Healer

DECEMBER 17, 2021

November 5, 2021. The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Hospital Pharmacy (2021): 0018578720985438. The Journal of Clinical Pharmacology 60.4

CBD 98

CBD THC Conditions Medicine 98

The Cannigma

DECEMBER 12, 2022

Scientists are hopeful that psychedelics might have more of a curative effect when it comes to mental health than many existing treatment options; meaning that unlike most psychiatric medications, psychedelics may be able to prompt long-term changes to our mental state with only a few doses. Are psychedelics safe?

History 119

History Microdosing Research and Development Clinical Trials 119

Veriheal

MAY 16, 2022

Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Specifically, the group focused on ketamine’s ability to relieve the side effects of a common treatment called Levodopa.

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

Healer

DECEMBER 17, 2021

November 5, 2021. The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Hospital Pharmacy (2021): 0018578720985438. [5] The Journal of Clinical Pharmacology 60.4

CBD 52

CBD THC Conditions Medicine 52

Veriheal

AUGUST 31, 2020

Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Nishtha Tripathi. Program between St.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

DECEMBER 9, 2021

The Financing is expected to close on December 10, 2021. The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.) 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144